[Report] Bristol-Myers Squibb Co PharmaVitae Profile Market Research ,Trends, Analysis TOC

CHAPTER 1 EXECUTIVE SUMMARY
- Key findings
- Historical and forecast ethical sales performance
- Therapeutic strategy
- Launch and expiry outlook
- Externalization, geographic and molecule type strategies
  - Externalization strategy
  - Geographic strategy
  - Molecule type strategy
- SWOT analysis
  - Strengths
  - Weaknesses
  - Opportunities
  - Threats
CHAPTER 2 CORPORATE HISTORY
- Key findings
- Background
- Key corporate developments/M&A history
  - Merger & acquisition speculation
- Current corporate structure
CHAPTER 3 HISTORICAL PERFORMANCE
- Key findings
- Introduction
- Revenue and growth rate analysis, 2001-06
  - Revenue and growth rate vs. peer set
- Product analysis, 2001-06
  - Growth drivers
    - Plavix
    - Abilify
    - Reyataz
    - Sustiva
  - Growth resistors
    - Glucophage
    - Pravachol
- Operating revenue and cost analysis, 2001-06
  - Operating revenue/cost analysis
CHAPTER 4 FORECAST PERFORMANCE
- Key findings
- Introduction
- Revenue and growth rate, 2006-12
- Product analysis, 2006-12
  - Growth drivers
    - Atripla
    - Orencia
    - Abilify
  - Growth resistors
    - Pravachol
    - Sustiva
    - Plavix
- Therapy area analysis, 2006-12
  - Therapy area growth drivers
  - Oncology
  - Immunology & inflammation
  - Infectious disease & central nervous system
  - Therapy area growth resistors
  - Cardiovascular & hematology
  - Therapy area focus
- Launches and expiries analysis, 2006-12
  - Launch portfolio
  - Core portfolio
  - Expiry portfolio
  - Launch/core/expiry configuration
- Externalization analysis, 2006-12
- Geographic analysis, 2006-12
- Molecule type analysis, 2006-12
CHAPTER 5 KEY PRODUCTS AND COMPETITORS
- Key findings
- Overview
- Cardiovascular & hematology
  - Plavix
    - Overview
    - Sales forecast
    - Newsflow
    - Current market assessment
    - Future market assessment: sales slowing through increased competition and the introduction of generics
  - Pravachol
    - Overview
    - Sales forecast
    - Newsflow
- Central nervous system
  - Abilify
    - Overview
    - Sales forecast
    - Newsflow
- Infectious diseases
  - Atripla
    - Overview
    - Sales forecast
    - Newsflow
  - Reyataz
    - Overview
    - Sales forecast
    - Newsflow
    - Future market assessment: threat from Prezista
- Oncology
  - Erbitux
    - Overview
    - Sales forecast
    - Newsflow
    - Future market assessment
  - Sprycel
    - Overview
    - Sales forecast
    - Newsflow
- Immunology & inflammation
  - Orencia
    - Overview
    - Sales forecast
    - Newsflow
- R&D pipeline
CHAPTER 6 APPENDIX
- IMS vs. company-reported data reconciliation
- References
- Abbreviations
- List of Tables
  - Table 1: Peer set overview
  - Table 2: Operating revenue/cost analysis ($m), 2001-06
  - Table 3: Operating cost ratio analysis (% of total revenues), 2001-06
  - Table 4: Product portfolio overview, sales ($m), 2006-12
  - Table 5: Therapy area overview, sales ($m), 2006-12
  - Table 6: Launch portfolio overview, sales ($m), 2006-12
  - Table 7: Core portfolio overview, sales ($m), 2006-12
  - Table 8: Expiry portfolio overview, sales ($m), 2006-12
  - Table 9: Externally developed portfolio ($m), 2006-12
  - Table 10: Molecule type overview, sales ($m), 2006-12
  - Table 11: Key products overview
  - Table 12: Plavix: overview
  - Table 13: Plavix: sales forecast ($m), 2006-12
  - Table 14: Plavix: newsflow
  - Table 15: Pravachol: overview
  - Table 16: Pravachol: sales forecast ($m), 2006-12
  - Table 17: Pravachol: newsflow
  - Table 18: Abilify: overview
  - Table 19: Abilify: sales forecast ($m), 2005-11
  - Table 20: Abilify: newsflow
  - Table 21: Atripla: overview
  - Table 22: Atripla: sales forecast ($m), 2006-12
  - Table 23: Atripla: newsflow
  - Table 24: Reyataz: overview
  - Table 25: Reyataz: sales forecast ($m), 2006-12
  - Table 26: Reyataz: newsflow
  - Table 27: Erbitux: overview
  - Table 28: Erbitux: sales forecast ($m), 2006-12
  - Table 29: Erbitux: newsflow
  - Table 30: Sprycel: overview
  - Table 31: Sprycel: sales forecast ($m), 2006-12
  - Table 32: Sprycel: newsflow
  - Table 33: Orencia: overview
  - Table 34: Orencia: sales forecast ($m), 2006-12
  - Table 35: Orencia: newsflow
  - Table 36: Bristol-Myers Squibb R&D pipeline (Phase I-registration)
- List of Figures
  - Figure 1: Historical and forecast ethical sales performance (% CAGR), Bristol-Myers Squibb and Big Pharma peer set
  - Figure 2: Therapeutic focus vs. Big Pharma peer set (%), 2006
  - Figure 3: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), Bristol-Myers Squibb
  - Figure 4: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), peer set
  - Figure 5: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2006
  - Figure 6: Molecule type, externalization and geographic market dependency (%) vs. peer set, 2012
  - Figure 7: SWOT analysis of Bristol-Myers Squibb
  - Figure 8: Revenue & growth rate (ethical sales) ($m), 2001-06
  - Figure 9: Ethical revenue ($m) and growth rate (%) vs. peer set, 2001-06
  - Figure 10: Growth drivers/resistor products of historical revenue performance ($m), 2001-06
  - Figure 11: Operating revenue/cost analysis ($m), 2001-06
  - Figure 12: Operating cost ratio analysis (% of total revenues), 2001-06
  - Figure 13: Ethical revenue ($m) and growth rate (%), 2006-12
  - Figure 14: Top five products by sales ($m), 2006
  - Figure 15: Top five products by sales ($m), 2012
  - Figure 16: Growth drivers and resistors by product, 2006-12
  - Figure 17: Key strategic products, sales ($m), 2006-12
  - Figure 18: Ethical sales by therapy area ($m), 2006-12
  - Figure 19: Growth drivers and resistors by therapy area (%), 2006-12
  - Figure 20: Ethical sales by therapy area (%), 2006-12
  - Figure 21: Therapy area focus compared with peer set (% total ethical sales), 2006
  - Figure 22: Therapy area focus compared with peer set (% total ethical sales), 2012
  - Figure 23: Launch schedule, sales ($m), 2006-12
  - Figure 24: Core products sales growth ($m), 2006-12
  - Figure 25: Expiry schedule, sales ($m), 2006-12
  - Figure 26: Launch, core and expiry, sales ($m), 2006-12
  - Figure 27: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), Bristol-Myers Squibb
  - Figure 28: Launch, core and expiry, absolute sales growth, 2006-12 (sales as % of 2006 sales), peer set
  - Figure 29: Externalization dependency, sales ($m), 2006-12
  - Figure 30: Growth drivers and resistors, externally vs. internally discovered products, sales ($m), 2006-12
  - Figure 31: Externalization dependency vs. peer set, % total sales, 2006
  - Figure 32: Externalization dependency vs. peer set, % total sales, 2012
  - Figure 33: Geographical sales breakdown ($m), 2006-12
  - Figure 34: Growth drivers and resistors by geography, sales ($m), 2006-12
  - Figure 35: US dependency vs. peer set, % total sales, 2006
  - Figure 36: US dependency vs. peer set, % total sales, 2012
  - Figure 37: Molecule type sales breakdown ($m), 2006-12
  - Figure 38: Growth drivers and resistors by molecule type, sales ($m), 2006-12
  - Figure 39: Biologics dependency vs. peer set, % total sales, 2006
  - Figure 40: Biologics dependency vs. peer set, % total sales, 2012
  - Figure 41: IMS vs. company-reported ethical sales discrepancy ($m), 2006
  - Figure 42: IMS vs. company-reported ethical sales forecast growth rates (%), 2006-12

Bristol-Myers Squibb Co.: PharmaVitae Profile

Table of Contents